Clinical trial
Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With…
NCT00496587 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00496587 |
|---|---|
| Title | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma |
| Official title | Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Kidney Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Gemcitabine, Bevacizumab |
| Enrollment | 34 |
| Start date | Jul 1, 2007 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2016 |
| First posted | Jul 4, 2007 |
| Last update posted | Jul 19, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: